Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 17/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | SIK1 | P57059 | 1/20 | 0.40 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.40 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 6/20 | 0.39 |
| ▸ | HTR3B | O95264 | 6/20 | 0.39 |
| ▸ | HTR3A | P46098 | 6/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 6/20 | 0.39 |
| ▸ | HTR3C | Q8WXA8 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7202680 | 0.95 | CHRNA7 (0.46) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7523653 | 0.81 | BRS3 (0.36) | ABL1 | |
| SCHEMBL7652150 | 0.81 | CHRNA7 (0.51) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6500451 | 0.75 | ABL1 (0.51) | CHRNA7ABL1SRCSIK1SIK2 | |
| SCHEMBL6496980 | 0.71 | HCAR2 (0.44) | ABL1 | |
| SCHEMBL6502838 | 0.71 | CHRNA7 (0.60) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL28474114 | 0.70 | ALDH1A1 (0.41) | ABL1 | |
| SCHEMBL7225133 | 0.69 | CHRNA7 (0.54) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7120966 | 0.69 | ABL1 (0.54) | CHRNA7ABL1SRCSIK1SIK2 | |
| SCHEMBL843533 | 0.69 | CTSK (0.47) | CHRNA7HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | MALT1, WFS1, NR5A1 | CHRNA7 1097/4885ABL1 853/4885SRC 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.